Physician profile
Stephen Arthur Hughes
NPI 1710185400
$682,684.14
in general payments reported to CMS, 2019-2025
15 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97K · 2020: $62K · 2021: $68K · 2022: $105K · 2023: $125K · 2024: $104K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $329K · Food and Beverage: $9,893 · Travel and Lodging: $7,357 · Consulting Fee: $4,000 · Education: $310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $329,061.78 |
| Food and Beverage | $9,892.78 |
| Travel and Lodging | $7,356.53 |
| Consulting Fee | $4,000.00 |
| Education | $309.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $269,083.20 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $222,635.89 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $115,270.90 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $47,633.84 | 2021-2025 | |
| Allergan, INC. | $14,888.92 | 2019-2020 | |
| Indivior INC. | $9,375.19 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,840.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $861.90 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $339.34 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $216.43 | 2019 | |
| Lundbeck LLC | $151.96 | 2021-2024 | Rexulti |
| Tris Pharma INC | $122.96 | 2019 | |
| Neurocrine Biosciences, INC. | $116.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $100.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.